Results of the German IPEP study evaluating tolerability, efficacy and acceptance of fulvestrant under routine clinical conditions in advanced breast cancer

1092 Background: Fulvestrant is used in the treatment of postmenopausal women with estrogen receptor-positive, locally advanced or metastatic breast cancer. The questions of the study are whether fulvestrant is safe, effective and tolerable. Methods: 848 patients were enrolled in this fulvestrant in practice evaluation programme (IPEP). Under clinical routine conditions in the participating centers regarding selection of subjects, diagnostic procedures or therapeutic decisions, all relevant data was documented over 9 months of fulvestrant therapy in postmenopausal women with advanced ER+ breast cancer who had relapsed during or after adjuvant anti- estrogen treatment, or with disease progression under palliative anti-estrogen therapy. Results: Data of 597 (70%) of patients was evaluable according to protocol. Median age was 64 years, 52% of patients had a co-morbidity, 78% one or more prior palliative therapies. Safety: 15.6% had one or more adverse events, mainly hot flushes, gastrointestinal, or musculo...